Our Focus and Why We Are Different
Bexmarilimab was discovered by Faron and is wholly owned. While the first wave of pioneering immunotherapies changed the face of cancer care, we aim to bring the promise of immunotherapy to a broader population. Novel treatments are still desperately needed and researchers continue to explore additional and complementary immunotherapeutic approaches.
Bexmarilimab is one of the most advanced myeloid cell-targeting immunotherapy candidates in development, within an emerging field of immunotherapy that is gaining scientific and clinical validation. In combination with standard-of-care in hematologic malignancies, bexmarilimab may improve the efficacy of current cancer treatments and bring the promise of immunotherapy to a broader population.
Our Mission
Faron is a global, clinical-stage biopharmaceutical company, focused on tackling cancers via novel immunotherapies. Our mission is to bring the promise of immunotherapy to a broader population by uncovering novel ways to control and harness the power of the immune system.
We are at the forefront of immunology and drug development. Since being founded in 2007, Faron has used our core scientific and clinical development expertise to advance academic discoveries with the potential to disrupt the current treatment landscape.
Our Unique Culture
Driving everything Faron does is a team of dedicated and talented professionals who share a commitment to working every day to deliver innovative medicines for cancer patients who have have run out of treatment options.
We have created an inclusive and empowering culture that embraces diverse experiences and perspectives of all our employees to drive innovation and transformative scientific and business results.
While the first wave of pioneering immunotherapies changed the face of cancer care, we need to bring the promise of immunotherapy to a broader population. Novel treatments are still desperately needed and researchers continue to explore additional and complementary immunotherapeutic approaches.”
Dr. Marie-Louise Fjällskog,Non-Executive Board Member
